Indication

Monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.

Medicine details

Medicine name:
gilteritinib (Xospata)
SMC ID:
SMC2252
Pharmaceutical company
Astellas Pharma Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q2 2020
SMC meeting date:
Q2 2020
Patient group submission deadline:
02 March 2020